Scarica l'app Stockscreener
4.11
0.48%
-0.02
Dopo l'orario di chiusura:
3.70
-0.41
-9.98%
Precedente Chiudi:
$4.13
Aprire:
$4.07
Volume 24 ore:
2,665
Relative Volume:
0.05
Capitalizzazione di mercato:
$5.12M
Reddito:
$12.99M
Utile/perdita netta:
$-27.83M
Rapporto P/E:
-0.0202
EPS:
-203.7366
Flusso di cassa netto:
$-26.98M
1 W Prestazione:
-6.38%
1M Prestazione:
-7.43%
6M Prestazione:
-43.47%
1 anno Prestazione:
-91.82%
Intervallo 1D:
$4.07
$4.11
Intervallo di 1 settimana:
$3.90
$4.45
Portata 52W:
$3.6803
$50.40
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Nome
Aptevo Therapeutics Inc
Settore
Industria
Telefono
206-838-0500
Indirizzo
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.11 | 5.25M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-11-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-10-05 | Ripresa | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie
APVO|Aptevo Therapeutics Inc|Price:4.209|Chg%:-0.181 - TradingKey
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo Therapeutics Unveils New Solid Tumor Strategy - TipRanks
Aptevo Dips on Credit Line - Baystreet.ca
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aptevo files patent for Nectin-4 x PD-L1 cancer platform - Investing.com
Aptevo Filing May Support Radiopharmaceuticals and T-Cell Engagers - Stock Titan
Aptevo Therapeutics Inc (APVO) Cash Flow - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Aptevo Therapeutics Inc. Revenue Breakdown – NASDAQ:APVO - TradingView
Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
APVO|Aptevo Therapeutics Inc|Price:4.390|Chg%:+0.020 - TradingKey
Mary Jo Janatpour Net Worth (2026) - GuruFocus
Niowave, Inc. Net Worth (2026) - GuruFocus
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo Therapeutics (APVO) Edges Higher: Testing Key Resistance Amid Steady VolumeBPI Reversal - dars.gov.et
Aptevo Therapeutics Secures Grant for APVO451 Development - The Globe and Mail
Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News
Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan
Aptevo receives $1.5M grant for cancer therapy development - Investing.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe
Aptevo gets $1.5M grant to advance a trispecific cancer drug - Stock Titan
Price to sales forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to sales forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics (APVO) Edges Lower, Testing Key Support LevelsFlat Correction - dars.gov.et
Price to book forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
APVO Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView
Aptevo Therapeutics (APVO) Gains 2.73% as Shares Test Key Resistance Near $4.95Corrective Wave - dars.gov.et
Aptevo Therapeutics, Inc. Actuals & Estimates (FWB:AP82) - TradingView
AP82 Forecast — Price Target — Prediction for 2027 - TradingView
Form 13G Aptevo Therapeutics Inc. For: 22 June By Investing.com - Investing.com South Africa
Niowave holds 12.18% of Aptevo (NASDAQ: APVO) — 151,723 shares - Stock Titan
NIOWAVE, INC. (NASDAQ: APVO) discloses 98,522 shares and $8 warrants - Stock Titan
Aptevo Therapeutics Inc (APVO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com
- The Legal Advocate
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Approach Support at $4.66Volume Climax - dars.gov.et
Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate
Aptevo Therapeutics (APVO) Holds Near Support After Modest DeclineHedge Fund Favorites - dars.gov.et
Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate
Aptevo Therapeutics Inc Azioni (APVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):